Citigroup
DYN icon

Citigroup’s Dyne Therapeutics DYN Stock Holding History

Citigroup’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$387K Buy
+24,000
New +$551K ﹤0.01% 3900

Other funds holding DYN

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
CenterBook Partners
CenterBook Partners Greenwich, Connecticut $2.18B AUM 12.5% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
Arizona State Retirement System
Arizona State Retirement System Phoenix, Arizona $20.3B AUM 36.55% 1-Year Est. Return

Citigroup's DYN Position: Q3 2026 in Review

Citigroup reduced its Dyne Therapeutics (DYN) stake by 48% in Q3 2026, selling an estimated $2.07M and leaving 97,934 shares worth $1.58M. The position accounts for ﹤0.01% of the portfolio, ranked #2996.

Citigroup first reported a position in DYN in Q4 2020 and has held it in 24 quarters since. The position peaked at $8.52M in Q1 2024. 62 funds tracked by Wall St. Rank hold DYN as of Q3 2026.

  • Citigroup held 97,934 shares of Dyne Therapeutics worth $1.58M as of Q3 2026.
  • Citigroup sold 89,981 Dyne Therapeutics shares in Q3 2026, an estimated $2.07M.
  • Dyne Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #2996 holding.
  • Citigroup first reported a position in Dyne Therapeutics in Q4 2020 and has held it in 24 quarters since.
  • Citigroup's Dyne Therapeutics position peaked at $8.52M in Q1 2024.
  • 62 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.